Umran Sumeyse Elbahr

Dr. Umran Sumeyse Elbahr


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2023 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
AKAmira Khairy
Amira Khairy
FDFarouq Dayyab
Farouq Dayyab
CRClark Steven Delos Reyes
Clark Steven Delos Reyes
JPJennie Pastrana
Jennie Pastrana
OSOguz Resat Sipahi
Oguz Resat Sipahi

1 June 2024
Verified
Journal Article
Closed access
AKAmira Khairy
Amira Khairy
SHSuha Hejres
Suha Hejres
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
FDFarouq Dayyab
Farouq Dayyab
CRClark Steven Delos Reyes
Clark Steven Delos Reyes
OSOguz Resat Sipahi
Oguz Resat Sipahi

24 March 2024 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
AAAmira Ahmed
Amira Ahmed
SHSuha Hejres
Suha Hejres
ZSZeki Surmeli
Zeki Surmeli
COCigdem Ozturk-Pala
Cigdem Ozturk-Pala
HEHakan Erdem
Hakan Erdem
Background: Appropriate empiric antibiotic use is of utmost importance in febrile neutropenic patients. This study analyzed positive blood culture reports from febrile neutropenic patients and provided a new empirical antibiotic treatment approach. Methods: This study retrospectively enrolled febrile neutropenic patients with hematological or solid organ malignancies who had positive blood cultures at the Bahrain Oncology Center within January 2019 to August 2021. Microbiological data were used to draw inferences for rational antimicrobial treatment. The quick sequential organ failure assessment (qSOFA) score was employed to classify the severity status. The t-test was used to compare univariate and multivariate sensitivity values for two dependent proportions. Results: A total of 73 episodes of bacteremia were detected in 53 patients. Among these, 54 episodes (74%) were caused by gram-negative organisms. The most commonly isolated organisms were Escherichia coli (30%), Klebsiella pneumonia (22%), and coagulase-negative staphylococci (11%). The rate of extensively drug-resistant strains among K. pneumoniae was 44% (n = 7). Among gram-negative microorganisms, the susceptibility rates for monotherapies were reported for ceftazidime (56%), piperacillin/tazobactam (76%), cefepime (54%), meropenem (80%), and ceftazidime-avibactam (91%). The susceptibility rates for tigecycline-based combinations exceeded 90% overall. Conclusions: Clinical severity and local epidemiological data should be considered in the management of febrile neutropenia. New antibiotics and tigecycline should be considered for combination therapy in selected cases due to the increasing resistance observed.

18 July 2025 in Medicine
Verified
Journal Article
Open access
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
HEHakan Erdem
Hakan Erdem
WYWissal Ben Yahia
Wissal Ben Yahia
Magdalena BaymakovaMagdalena Baymakova
Magdalena Baymakova
ALAmel Letaief
Amel Letaief
OSOguz Resat Sipahi
Oguz Resat Sipahi
Herein, we aimed to analyze the final diagnosis in a well-defined cohort of fever of unknown origin (FUO) cases whose erythrocyte sedimentation rate (ESR) was 100 mm/h or more during the admission. The subgroup of the FUO patients with an ESR of 100 mm/h or more during the FUO evaluation, was extracted from the study database of a previously published multicenter study (European Journal of Clinical Microbiology & Infectious Diseases. April 15, 2023;42 (4):387–98). Data for 139 patients (17.6%, 139/788 of the original cohort) who fulfilled the study inclusion criteria, were obtained from 29 centers from 11 countries. Infections, neoplasms, and noninfectious inflammatory diseases were found to be the reason of fever in [n = 74 (53.2%)], [n = 14 (10%)], and [n = 13 (9.3%)] of 139 patients, respectively. Regardless of the diseases subgroup top 6 diseases that were determined to be the reasons of FUO were tuberculosis [n = 15 (10.8%)], HIV/AIDS [n = 13 (9.3%)], urinary tract infection [n = 9 (6.5%)], infective endocarditis [n = 9 (6.5%)], lymphoma [n = 9 (6.5%)], and abscess [n = 9 (6.5%)]. The most common infectious diseases were tuberculosis (15/74, 20.2%), HIV/AIDS (13/74, 17.5%), and infective endocarditis (9/74, 12.1%), along with urinary tract infection [n = 9 (6.5%)] and abscess [n = 9 (6.5%)]. The most common noninfectious inflammatory diseases were adult onset Still disease (3/13, 23%) and giant cell arteritis, also known as temporal arteritis (3/13, 23%), and followed by polyarteritis nodosa (2/13, 15.3%). The most common neoplasm was lymphoma (9/14, 64.2%), followed by lung cancer (2/14, 14.2%). Reason of fever could not be defined in (29/139, 20.8%) patients. The invasive procedures were performed in (64/139, 46%) patients. Gender, age > 50 or not, and income level (high–middle–low) of the participating country were not associated with a significant difference in the final diagnosis category of the FUO case (P > .05). To the best of our knowledge, this is the first study evaluating the FUO in the subgroup of cases with extreme ESR elevation and infectious diseases comprised the most cause of the FUO in this particular subgroup.

4 July 2025 in Mediterranean Journal of Infection Microbes and Antimicrobials
Verified
Journal Article
Open access
PDF file
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
NANafisa Alwazzan
Nafisa Alwazzan
CRClark Steven Delos Reyes
Clark Steven Delos Reyes
JPJennie Pastrana
Jennie Pastrana
CVChithra Vineeth
Chithra Vineeth
OSOguz Resat Sipahi
Oguz Resat Sipahi
Hand Hygiene Compliance Rates and the Interventions to Increase Hand Hygiene Compliance Among Healthcare Workers in a Tertiary-Care Educational Hemato-Oncology Hospital: A Prospective Observational Study - Mediterranean Journal of Infection Microbes and Antimicrobials

11 May 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
UEUmran Sumeyse Elbahr
Umran Sumeyse Elbahr
HEHakan Erdem
Hakan Erdem
ALAmel Letaief
Amel Letaief
SGSvjetlana Grgić
Svjetlana Grgić
LZLysien Ivania Zambrano
Lysien Ivania Zambrano
OSOğuz Reşat Sipahi
Oğuz Reşat Sipahi
In fever of unknown origin (FUO), despite comprehensive evaluation a substantial proportion of patients may remain without a definitive diagnosis. Herein, we aimed to analyse the disease course, mortality rate, final diagnosis, and the workup performed to reach final diagnosis in fever of unknown origin without final diagnoses (FUOWFD) cases. The roster of patients with FUOWFD was obtained from a previously published multicenter study. Subsequently, additional data was gathered retrospectively from each cooperating center. The follow-up data for 79 cases from 11 centers were included. While being considered as FUOWFD: 100% were performed biochemistry and microbiology, 78.5% for rheumatological markers, 33% for oncological markers, and 97.5% for radiological investigations. Other medical departments were consulted in 64.5% of the cases and invasive diagnostic procedures were performed in 27.8%. During the follow-up, 73 cases (92.4%) saw their fever resolve. Among these, 70 cases' fever resolved within the first three months. In total, two patients (2.5%) received a definitive diagnosis during the follow-up period. After 6 months and 12 months follow up, the all-cause mortality rate was 3.8%. Notably, none of the three cases that experienced mortality by day 365 had received a final diagnosis for FUO. The diagnostic process for FUO cases who remain undiagnosed exhibits substantial heterogeneity. The majority of patients experience spontaneous recovery, and the mortality rate is relatively low. Infectious causes are the most frequently encountered contributors to the FUO cases who remain undiagnosed. Not applicable.